國立成功大學醫學院 婦產學科
許耿福 教授

Professor Keng-Fu Hsu

連絡電話： (06)2353535 #5623 (研究室) #3137 (實驗室)
E-mail： d5580@mail.ncku.edu.tw

學歷
國立成功大學醫學院 臨床醫學研究所 博士(2008)

研究專長
臨床醫學、腫瘤醫學、轉譯醫學

研究興趣
卵巢癌及子宮內膜癌為婦女癌症中最不易治療及最高發生率的癌症。 卵巢癌的抗藥性（對於化學治療後復發腫瘤）一直是治療病人成功的阻礙。 另外，對於亮細胞卵巢癌(clear cell ovarian cancer)的預後不良也是困擾臨床治療的問題。 同時，針對轉移、復發子宮內膜癌病人，直到今日，醫學界仍沒有較好的治療方式， 這些要解決的臨床問題，均是本實驗室有興趣研究的題目。

研究方向
● 使用全基因次世代定序，利用臨床子宮內膜癌腫瘤組織找到可能的預後因子，及可能之調控機轉。
● 使用微陣列晶片及病人臨床資料，尋求亮細胞卵巢癌之生物標誌，結合微流體技術及病人臨床檢體， 發展新型診斷工具。

Publications:

  1. Yeong-Chang Chen, Meng-Ru Shen, Ai-Li Shiau, Hamm-Ming Sheu, Yu-Lin Liang and Keng-Fu Hsu. ( Corresponding author) A Solanum incanum extract (SR-T100) regresses vulvar condyloma acuminatum and induces distinct autophagic and apoptotic responses in different types of HPV-infected cells. Translational Medicine Communications 2017;2:8. DOI 10.1186/s41231-017-0017-

  2. Yu-Min Yeh, Shan-Ju Hsu, Peng-Chan Lin, Keng-Fu Hsu, Pei-Ying Wu, Wu-Chou Su, Jang-Yang Chang, Meng-Ru Shen. The c.1085A>G genetic variant of CSF1R gene regulates tumor immunity by altering the proliferation, polarization,and function of macrophages. Clinical Cancer Res , 2017 Oct 15;23(20):6021-6030. doi: 10.1158/1078-0432.

  3. Yi-Ying Wu, Chia-Lin Chang, Yuan-Jhe Chuang, Jia-En Wu, Chia-Hao Tung, Yeong-Chang Chen, Yuh-Ling Chen, Tse-Ming Hong, and Keng-Fu Hsu. ( Corresponding author) CASZ1 is a novel promoter of metastasis in ovarian cancer. Am J Cancer Res 2016; 6(6):1253-1270.

  4. Hsu IL, Chou CY, Wu YY, Wu JE, Liang CH, Tsai YT, Ke JY, Chen YL, Hsu KF, Hong TM. ( Co-Corresponding author) Targeting FXYD2 by cardiac glycosides potently blocks tumor growth in ovarian clear cell carcinoma. Oncotarget. 2016 Sep 27;7(39):62925-62938.

  5. Chen YF, Hsu KF, Shen MR. The store-operated Ca2+ entry-mediated signaling is important for cancer spread. Biochim Biophys Acta. Biochim Biophys Acta. 2016 Jun; 1863(6 Pt B):1427-35.

  6. Hsu KF, Shen MR, Huang YF, Cheng YM, Lin SH, Chow NH, Cheng SW, Chou CY, Ho CL. Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer. Br J Cancer. 2015 Jul 28;113(3):414-24. doi: 10.1038/bjc.2015.254.

  7. Hsu KF, Chou HH, Huang CY, Fu HC, Chiang AJ, Tsai HW, Chen JR, Cheng WF, Ke YM, Chang CC, Chen TH, Lin SH, Ho CM. Prognostic factors and treatment outcomes for patients with surgically staged uterine clear cell carcinoma focusing on the early stage: A Taiwanese Gynecologic Oncology Group study. Gynecol Oncol. 2014 Sep;134(3):516-22. doi: 10.1016/j.ygyno.2014.07.005.

  8. Huang YF, Cheng WF, Wu YP, Cheng YM, Hsu KF, Chou CY. Circulating IGF system and treatment outcome in epithelial ovarian cancer. Endocr Relat Cancer. 2014 Jan 30;21(2):217-29.

  9. Chih-Hung Wang, Hsien-Chih Lai, Tong-Miin Liou, Keng-Fu Hsu, Cheng-Yang Chou, Gwo-Bin Lee. A DNA methylation assay for detection of ovarian cancer cells using a HpaII/MspI digestion-based PCR assay in an integrated microfluidic system Microfluidics and Nanofluidics. 2013;15( 5): 575.